Epista生命科学正在为一家全球制药公司800多项研究和400万份文件提供补救数据,以提高准确性、合规性和数字准备程度。 Epista Life Science is remediating data across 800+ studies and 4 million documents for a global pharma company to boost accuracy, compliance, and digital readiness.

Epista生命科学与一家全球制药公司一起发起了一项重大的临床数据补救工作,处理了800多项研究和400万份文件,以提高数据准确性、合规性和数字系统的准备状态。 Epista Life Science has launched a major clinical data remediation effort with a global pharmaceutical company, addressing over 800 studies and 4 million documents to improve data accuracy, compliance, and readiness for digital systems. 该多阶段方案是这类方案中规模最大的 " Epista " 方案,旨在加强试验管理,支持下一代CTMS,并加强数据治理。 The multi-phase program, the largest of its kind for Epista, aims to enhance trial management, support a next-generation CTMS, and strengthen data governance. 它利用Epista的方法和DNANexus平台使数据标准化,确保实时监管监督,并为先进的分析和AI做准备。 It leverages Epista’s methodology and the DNANexus platform to standardize data, ensure real-time regulatory oversight, and prepare for advanced analytics and AI. 该倡议旨在降低检查风险,加快研究的启动,并建立一个值得信赖的未来准备数据基础,标志着该行业在推动提高数据质量和透明度方面迈出了重要的一步。 The initiative is designed to reduce inspection risks, speed up study startup, and build a trusted, future-ready data foundation, marking a significant step in the industry’s push for higher data quality and transparency.